Iacocca foundation backs autoimmune program at Kineta

Like every small biotech, Seattle-based Kineta is always on the lookout for new investors and negotiating the best deal terms it can get. Along those lines, the developer gained a prize addition to its list of backers with word that Lee Iacocca's family foundation is putting some of its money behind one of Kineta's autoimmune disease programs (ShK-186). Iacoccas's first wife died of diabetes. And like a lot of foundations which are getting involved in finding new drugs, it's more interested in a better therapy than making money on its investments. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.